State of Alaska Department of Revenue Has $1.82 Million Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

State of Alaska Department of Revenue boosted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 6.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,427 shares of the company’s stock after buying an additional 1,965 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.07% of Pacira BioSciences worth $1,815,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Pacira BioSciences by 4.8% in the 2nd quarter. Vanguard Group Inc. now owns 4,724,929 shares of the company’s stock valued at $286,709,000 after purchasing an additional 218,398 shares during the last quarter. Macquarie Group Ltd. raised its position in Pacira BioSciences by 12.9% in the 2nd quarter. Macquarie Group Ltd. now owns 3,715,264 shares of the company’s stock valued at $225,442,000 after purchasing an additional 423,133 shares during the last quarter. Baillie Gifford & Co. raised its position in Pacira BioSciences by 0.3% in the 2nd quarter. Baillie Gifford & Co. now owns 2,102,759 shares of the company’s stock valued at $127,595,000 after purchasing an additional 7,278 shares during the last quarter. State Street Corp raised its position in Pacira BioSciences by 3.2% in the 2nd quarter. State Street Corp now owns 1,476,967 shares of the company’s stock valued at $89,622,000 after purchasing an additional 45,127 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its position in Pacira BioSciences by 95.5% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,030,645 shares of the company’s stock valued at $62,540,000 after purchasing an additional 503,548 shares during the last quarter.

NASDAQ:PCRX opened at $54.25 on Thursday. Pacira BioSciences, Inc. has a 1 year low of $45.05 and a 1 year high of $80.00. The company has a current ratio of 3.64, a quick ratio of 3.34 and a debt-to-equity ratio of 0.45. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of 39.89 and a beta of 0.97. The stock has a 50-day moving average price of $54.57 and a two-hundred day moving average price of $57.74.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Tuesday, November 2nd. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.07. Pacira BioSciences had a return on equity of 14.39% and a net margin of 12.01%. The firm had revenue of $127.70 million during the quarter, compared to analysts’ expectations of $129.69 million. During the same period in the previous year, the firm earned $0.43 earnings per share. The company’s revenue was up 8.7% on a year-over-year basis. Sell-side analysts forecast that Pacira BioSciences, Inc. will post 1.94 earnings per share for the current year.

A number of research firms have recently weighed in on PCRX. Barclays boosted their target price on Pacira BioSciences from $91.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, November 5th. TheStreet upgraded Pacira BioSciences from a “c+” rating to a “b” rating in a research report on Monday, August 9th. BMO Capital Markets dropped their target price on Pacira BioSciences from $66.00 to $60.00 and set a “market perform” rating for the company in a research report on Tuesday, October 12th. Needham & Company LLC boosted their target price on Pacira BioSciences from $80.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, October 18th. Finally, Zacks Investment Research downgraded Pacira BioSciences from a “hold” rating to a “strong sell” rating and set a $48.00 target price for the company. in a research report on Tuesday, September 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $76.92.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Read More: What is the float in trading stocks?

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.